![Clinical significance of neutrophil CD177 mRNA expression in Ph‐negative chronic myeloproliferative disorders - Passamonti - 2004 - British Journal of Haematology - Wiley Online Library Clinical significance of neutrophil CD177 mRNA expression in Ph‐negative chronic myeloproliferative disorders - Passamonti - 2004 - British Journal of Haematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/a3e8678c-81d5-467b-be71-25babb4d8c25/bjh.v194.2.cover.jpg)
Clinical significance of neutrophil CD177 mRNA expression in Ph‐negative chronic myeloproliferative disorders - Passamonti - 2004 - British Journal of Haematology - Wiley Online Library
![Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis | Request PDF Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis | Request PDF](https://i1.rgstatic.net/publication/303800842_Personal_history_and_quality_of_life_in_chronic_myeloid_leukemia_patients_a_cross-sectional_study_using_narrative_medicine_and_quantitative_analysis/links/5f74868e299bf1b53e006af4/largepreview.png)
Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis | Request PDF
![Incidence and outcomes of paediatric myelodysplastic syndrome in the United States - Xavier - 2018 - British Journal of Haematology - Wiley Online Library Incidence and outcomes of paediatric myelodysplastic syndrome in the United States - Xavier - 2018 - British Journal of Haematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/ce6558c9-9b89-4c5b-aeb6-233c5377a873/bjh.14460.fp.png)
Incidence and outcomes of paediatric myelodysplastic syndrome in the United States - Xavier - 2018 - British Journal of Haematology - Wiley Online Library
A 4.8mW inductorless CMOS frequency divider-by-4 with more than 60% fractional bandwidth up to 70GHz
REFERENCE REFERENCES CYCLOPHOSPHAMIDE OR CHLORAMBUCIL THERAPY IS INDICATED IN IDIOPATHIC MEMBRANOUS NEPHROPATHY WITH STRONG RISK
World Mobile Token on Twitter: "@SundaeSwap @MinswapDEX @wingriderscom @MuesliSwapTeam @realmilkyswap @AstroSwapApp @occamDEX" / Twitter
![Interferon Alfa-2a as Compared with Conventional Chemotherapy for the Treatment of Chronic Myeloid Leukemia | NEJM Interferon Alfa-2a as Compared with Conventional Chemotherapy for the Treatment of Chronic Myeloid Leukemia | NEJM](https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/1994/nejm_1994.330.issue-12/nejm199403243301204/production/images/img_medium/nejm199403243301204_f1.jpeg)
Interferon Alfa-2a as Compared with Conventional Chemotherapy for the Treatment of Chronic Myeloid Leukemia | NEJM
![PDF) High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study PDF) High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study](https://i1.rgstatic.net/publication/41419669_High-dose_imatinib_improves_cytogenetic_and_molecular_remissions_in_patients_with_pretreated_Philadelphia-positive_BCR-ABL-positive_chronic_phase_chronic_myeloid_leukemia_first_results_from_the_random/links/0912f50ca0d342b8fc000000/largepreview.png)
PDF) High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study
![FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells | Leukemia FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells | Leukemia](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fsj.leu.2404510/MediaObjects/41375_2007_Article_BF2404510_Fig2_HTML.jpg)
FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells | Leukemia
![Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study | Blood Cancer Journal Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study | Blood Cancer Journal](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41408-020-0333-2/MediaObjects/41408_2020_333_Fig1_HTML.png)
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study | Blood Cancer Journal
![Differences among young adults, adults and elderly chronic myeloid leukemia patients - Annals of Oncology Differences among young adults, adults and elderly chronic myeloid leukemia patients - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/abbe1916-9ac3-4672-b314-3cbbe701c970/gr1_lrg.jpg)
Differences among young adults, adults and elderly chronic myeloid leukemia patients - Annals of Oncology
![Frontiers | Perspectives and Emotional Experiences of Patients With Chronic Myeloid Leukemia During ENESTPath Clinical Trial and Treatment-Free Remission: Rationale and Protocol of the Italian Substudy Frontiers | Perspectives and Emotional Experiences of Patients With Chronic Myeloid Leukemia During ENESTPath Clinical Trial and Treatment-Free Remission: Rationale and Protocol of the Italian Substudy](https://www.frontiersin.org/files/Articles/638689/fonc-11-638689-HTML-r1/image_m/fonc-11-638689-g001.jpg)
Frontiers | Perspectives and Emotional Experiences of Patients With Chronic Myeloid Leukemia During ENESTPath Clinical Trial and Treatment-Free Remission: Rationale and Protocol of the Italian Substudy
Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers | Haematologica
![PDF) Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty PDF) Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty](https://i1.rgstatic.net/publication/236783707_Bone_metabolism_growth_rate_and_pubertal_development_in_children_with_chronic_myeloid_leukemia_treated_with_imatinib_during_puberty/links/568f873408ae78cc0517afd4/largepreview.png)
PDF) Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty
![Cancers | Free Full-Text | Multiparametric Flow Cytometry for MRD Monitoring in Hematologic Malignancies: Clinical Applications and New Challenges | HTML Cancers | Free Full-Text | Multiparametric Flow Cytometry for MRD Monitoring in Hematologic Malignancies: Clinical Applications and New Challenges | HTML](https://www.mdpi.com/cancers/cancers-13-04582/article_deploy/html/images/cancers-13-04582-g001.png)